Intensified Regression of Colon Cancer Liver Metastases in Mice Treated with Irinotecan and the Immunomodulator JBT 3002
Authors:
- Corazon D. BucanaCBCorazon D. Bucana
- Jerald J. KillionJKJerald J. Killion
- Isaiah J. FidlerIFIsaiah J. Fidler
- 1 May 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 23 (3) , 321-331
Abstract
The authors recently reported that tumoricidal activation of macrophages by a new synthetic bacterial lipopeptide, JBT 3002, can augment chemotherapy-mediated tumor-cell killing. The aim of this study was to identify the mechanism responsible for the destruction of metastatic cells. Three daily oral doses of JBT 3002 before once-weekly intraperitoneal injections of 100 mg/kg irinotecan for 3 weeks significantly increased the eradication of established CT-26 murine colon cancer liver metastases compared with treatment with irinotecan alone. Immunohistochemical analyses revealed that the hepatic metastases in mice given combination therapy contained infiltrating CD8+ lymphocytes and a dense infiltrate of macrophages expressing both inducible nitric oxide synthase (iNOS) and interleukin-15. In vitro treatment of peritoneal macrophages with JBT 3002 plus interferon-γ induced the expression of iNOS and the production of nitric oxide. In the presence of a low (subtoxic) dose of irinotecan, these activated macrophages produced significant lysis of CT-26 cells. The high level of cytotoxicity was inhibited by the specific inducible nitric oxide synthase inhibitor, NG-methyl-L-arginine. In contrast, irinotecan-mediated lysis of normal intestinal epithelial IEC-6 cells was not increased by activated macrophages. Scanning electron microscopy revealed that activated macrophages bound to CT-26 tumor cells but not to normal IEC-6 cells, confirming that nitric oxide–mediated cytotoxicity is specific for tumor cells. Collectively, the results suggest that augmentation of the therapeutic efficacy of irinotecan against colon cancer liver metastases by immunomodulation with JBT 3002 may be associated with elevated inducible nitric oxide synthase and endogenous interleukin-15 in tumor-infiltrating macrophages.Keywords
This publication has 21 references indexed in Scilit:
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Destruction of Bystander Cells by Tumor Cells Transfected With Inducible Nitric Oxide (NO) Synthase GeneJNCI: Journal of the National Cancer Institute, 1997
- Intestinal epithelial cells both express and respond to interleukin 15Gastroenterology, 1996
- Characterisation and Clinical Management of CPT-11 (Irinotecan)-induced Adverse Events: The European PerspectiveEuropean Journal of Cancer, 1996
- Efficacy of CPT-11 (Irinotecan) as a Single Agent in Metastatic Colorectal CancerEuropean Journal of Cancer, 1996
- Irinotecan (CPT-11) and Characteristic Mucosal Changes in the Mouse Ileum and CecumJNCI: Journal of the National Cancer Institute, 1995
- Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.Journal of Experimental Medicine, 1994
- Nitric oxide synthases: Roles, tolls, and controlsCell, 1994
- Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 ReceptorScience, 1994
- Secretory products of macrophages.Journal of Clinical Investigation, 1987